NAS:SRRK (USA) Also Trade In: Germany
Scholar Rock Holding Corp $ 13.91 0.15 (1.09%)
Warning! GuruFocus has detected 3 Severe warning signs with SRRK. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for SRRK (Scholar Rock Holding Corp) from 2018 to Oct 22 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Scholar Rock Holding stock (SRRK) PE ratio as of Oct 22 2020 is 0. More Details
Scholar Rock Holding PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Scholar Rock Holding PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:CLVS NAS:VNDA NAS:MGTX NAS:PRVL NAS:HARP NAS:STML NAS:ATHX NAS:CRBP NAS:CRNX NAS:NERV OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 620 Memorial Drive, 2nd Floor, Cambridge, MA, USA, 02139
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle.